Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials (2021 - 2024)

Apellis Pharmaceuticals (APLS) has 4 years of Raw Materials data on record, last reported at $42.1 million in Q1 2024.

  • For Q1 2024, Raw Materials rose 23.98% year-over-year to $42.1 million; the TTM value through Mar 2024 reached $42.1 million, up 23.98%, while the annual FY2023 figure was $32.7 million, 9.64% up from the prior year.
  • Raw Materials reached $42.1 million in Q1 2024 per APLS's latest filing, up from $32.7 million in the prior quarter.
  • Across five years, Raw Materials topped out at $42.1 million in Q1 2024 and bottomed at $5.7 million in Q4 2021.
  • Average Raw Materials over 4 years is $26.3 million, with a median of $28.0 million recorded in 2022.
  • Peak YoY movement for Raw Materials: skyrocketed 419.17% in 2022, then rose 0.75% in 2023.
  • A 4-year view of Raw Materials shows it stood at $5.7 million in 2021, then surged by 419.17% to $29.8 million in 2022, then rose by 9.64% to $32.7 million in 2023, then rose by 28.62% to $42.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $42.1 million in Q1 2024, $32.7 million in Q4 2023, and $26.2 million in Q3 2023.